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ABSTRACT 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairments. A major 
histopathological hallmark of AD is the presence of amyloid deposits in the parenchyma of the amygdala, hippocampus, and 
neocortex. β-amyloid is a small piece of a larger protein called “amyloid precursor protein” (APP). The main component of amyloid 
is the β-Amyloid protein (Aβ), a 39.43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular 
domain of the APP. Aβ deposition leads to synaptic degeneration and interacts with different types of central nervous system 
receptors; hence, it disrupts neuronal homeostasis. Moreover, Aβ deposition along the cerebral vessels alters their tonicity and 
triggers some of the cerebrovascular deficits. Furthermore, its accumulation disrupts intracellular Ca2+ homeostasis which 
ultimately reduces neuronal Ca2+ buffering capacity and increases excitotoxicity outcomes. The emerging approach is to bypass the 
BBB by intranasal delivery, which provides a practical, noninvasive, rapid and simple method to deliver the therapeutic agents to the 
CNS. This method works the unique connection between the nose and the brain that has evolved to sense odors and other chemical 
stimuli. On the basis of clinical trials (Phase I and II) it is reported that the intranasal route is feasible for the transport of the drug to 
the CNS. Intranasal delivery does not require any modification of the therapeutic agents and does not require that drugs be coupled 
with any carrier like in case of drug delivery across the BBB. A wide variety of therapeutic agents, including both small molecules 
and macromolecules can be successfully delivered, including to the CNS, using the intranasal method. 
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INTRODUCTION 
The blood–brain barrier (BBB) is located at the level of 
the cerebral microvasculature and is critical for maintain 
central nervous system (CNS) homeostasis. Although 
the BBB restricts the entry of potentially neurotoxic 
substances in the brain, it also presents a major obstacle 
to the delivery of therapeutics into the CNS for disease 
treatment. The BBB exhibits a small rate of pinocytosis 
and possesses tight junctions (TJ) which form a seal 
between opposing endothelial membranes 
1
. The 
presence of TJ at the BBB creates a high 
transendothelial electrical resistance of 1500–2000 
Ω∙cm2 compared to 3–30 Ω∙cm2 across most peripheral 
microvessels 
2,3
. This high resistance is associated with 
very low permeability, i.e. the BBB greatly restricts 
paracellular diffusion of solutes from the blood into the 
brain. Typically, only minute, lipophilic molecules 
appreciably cross the normal, healthy BBB via 
transcellular passive diffusion, although some limited 
transport of certain peptides and peptide analogs has 
been reported 
4
. Essential nutrients such as glucose or 
iron gain entry into the CNS through specific 
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transporters such as the glucose transporter 1 or 
receptors such as the transferrin receptor 
5,6
. Receptors 
and transporters for gastrointestinal hormones involved 
in regulating metabolism are expressed at the BBB in 
order to convey information between the CNS and 
periphery
 7
. In addition to its low paracellular 
permeability and low rate of pinocytosis, the BBB also 
expresses a high number of drug transporters (e.g. P-
glycoprotein) which further restrict brain entry of many 
endogenous and exogenous substances that would 
otherwise be predicted to cross the BBB based on 
molecular weight (MW) and lipophilicity considerations 
8,9
. 
Although there are many examples of small MW drugs 
which cross the BBB, nearly all large MW substances 
are severely restricted from crossing the BBB under 
normal conditions; indeed, the only examples of large 
MW drugs approved for clinical use in treating a 
neurological illness are those that act via peripheral 
mechanisms. Many large MW substances have shown 
substantial promise in treating aspects of CNS diseases 
based on studies utilizing in vitro systems and animal 
models. However, it will likely be necessary to 
implement drug delivery strategies that overcome the 
formidable obstacles presented by the various barriers of 
the CNS (the BBB and blood–cerebrospinal fluid (CSF) 
barriers) for these studies to ultimately be translated to 
the clinic 
10
. Intraparenchymal, intracerebroventricular, 
and intrathecal injections/infusions are capable of 
delivering therapeutics directly to the CNS, but these 
routes of administration are invasive and likely not 
practical for drugs which need to be given chronically. 
The intranasal (IN) route of administration provides a 
non-invasive method of bypassing the BBB to 
potentially deliver biologics such as peptides, proteins, 
oligonucleotides, viral vectors, and even stem cells to 
the CNS. 
OVERVIEW OF ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a degenerative brain 
disease and the most common cause of dementia. 
Dementia is characterized by a decline in memory, 
language, problem solving and other cognitive skills that 
affects a person’s ability to perform everyday activities. 
This decline occurs because nerve cells (neurons) in 
parts of the brain involved in cognitive function have 
been damaged or destroyed. In Alzheimer’s disease, the 
damage and destruction of neurons eventually affects 
other parts of the brain, including those that enable a 
person to carry out basic bodily functions such as 
walking and swallowing. People in the final stages of 
the disease are bed-bound and require around-the-clock 
care. Alzheimer’s disease is ultimately fatal. 
Dementia 
Physicians may refer to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) to guide them in 
determining if an individual has dementia, and, if so, 
what may be the cause. Based on the latest DSM criteria 
11
, dementia is classified as a major neurocognitive 
disorder because it interferes with both cognitive 
function and performing everyday activities. Cognitive 
function refers to memory, speech, language, judgment, 
reasoning, planning and other thinking abilities. 
Examples of everyday activities are making a meal, 
paying bills, and traveling to a store to make a purchase. 
When an individual has symptoms of dementia, such as 
memory or language problems, a physician will conduct 
tests to identify the cause. Studies indicate that many 
people with dementia, especially those in the older age 
groups, have brain abnormalities associated with more 
than one cause of dementia 
12,13
. This condition is called 
mixed dementia. 
In some cases, individuals with symptoms of dementia 
do not have dementia, but instead have a condition 
whose symptoms mimic those of dementia. Common 
causes of dementia like symptoms are depression, 
delirium, side effects from medications, thyroid 
problems, certain vitamin deficiencies and excessive use 
of alcohol. Unlike dementia, these conditions often may 
be reversed with treatment. One meta-analysis, a method 
of analysis in which results of multiple studies are 
examined, reported that 9 percent of people with 
dementia-like symptoms did not in fact have dementia, 
but had other conditions that were potentially reversible 
14
. 
Alzheimer’s disease 
Alzheimer’s disease was first identified more than 100 
years ago, but 70 years passed before it was recognized 
as the most common cause of dementia, as well as a 
major cause of death 
15
. Not until then did Alzheimer’s 
disease become a significant area of research. Although 
the research that followed has revealed a great deal 
about Alzheimer’s, much is yet to be discovered about 
the precise biological changes that cause Alzheimer’s, 
why it progresses more quickly in some than in others, 
and how the disease can be prevented, slowed or 
stopped. 
Researchers believe that early detection of Alzheimer’s 
will be key to preventing, slowing and stopping the 
disease. The last 10 years have seen tremendous growth 
in research on early detection. This research spurred the 
2011 publication of new diagnostic criteria and 
guidelines for Alzheimer’s disease 16,17. According to 
the criteria, the brain changes of Alzheimer’s begin 
before symptoms such as memory loss appear, whereas 
earlier criteria require memory loss and a decline in 
thinking abilities for an Alzheimer’s diagnosis to be 
made. Because scientific evaluation of some 
components of the new criteria is ongoing, “Alzheimer’s 
disease” in this report refers to the disease as defined by 
the earlier criteria 
18
. 
Symptoms 
The most common initial symptom is a gradually 
worsening ability to remember new information. This 
occurs because the first neurons to be damaged and 
destroyed are usually in brain regions involved in 
forming new memories. As neurons in other parts of the 
brain are damaged and destroyed, individuals experience 
other difficulties. The following are common symptoms 
of Alzheimer’s: 
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 Memory loss that disrupts daily life. 
 Challenges in planning or solving problems. 
 Difficulty completing familiar tasks at home, at 
work or at leisure. 
  Confusion with time or place. 
  Trouble understanding visual images and spatial 
relationships. 
  New problems with words when speaking or 
writing. 
  Misplacing things and losing the ability to retrace 
steps. 
  Decreased or poor judgment. 
 Withdrawal from work or social activities. 
 Changes in mood and personality, including apathy 
and depression. 
 Increased anxiety, agitation and sleep disturbances. 
PATHOPHYSIOLOGY OF ALZHEIMER’S 
DISEASE 
With pathophysiology of AD, debate goes back to the 
Alzheimer’s time 1907 when he observed the 
neuropathological features of the disease i.e. amyloidal 
plaques and hyperpho-sphorylated NFTs. Several 
hypotheses have been put forward on the basis of the 
various causative factors in order to explain this 
multifactorial disorder 
19
 such as the cholinergic 
hypothesis, Aβ hypothesis, tau hypothesis and 
inflammation hypothesis 
20
. Recently it has been shown 
that the most commonly used Aβ hypotheses, prevailing 
for the last two decades, does not account for the 
complex pathophysiology of this incapacitating disease 
21. Recent studies have also highlighted the role of Aβ 
oligomers in synaptic impairment, suggesting that these 
are primarily the only one among several other signals 
that destroy the integrity of brain functions 
22,21,23,24
. And 
formations of amyloid plaques that develop in the later 
age appear to be rather late event 
23
. 
According to the amyloid cascade hypothesis, the APP 
is normally cleaved by α-secretase and aberrantly 
processed by β- and γ-secretases (Fig. 1) resulting in an 
imbalance between  production and clearance of Aβ 
peptide 
25. As a consequence, Aβ peptides 
spontaneously aggregate into soluble oligomers and 
coalesce to form fibrils insoluble beta-sheet 
conformation and are eventually deposited in diffuse 
senile plaques 
21
. Some recent studies have shown that 
Aβ42 oligomers are produced by cooperative activities 
of both neurons and its associated astrocytes 
23
. It has 
been observed that Aβ42 oligomers induce oxidative 
damage, promote tau hyperphosphorylation, results in 
toxic effects on synapses and mitochondria 
20,19
. But the 
role of Aβ42 senile plaques cannot be ignored as Aβ42 
plaques that are supposed to be appearing during late 
stage attract microglia 
26
. Microglial activation results in 
production and release of pro-inflammatory cytokines, 
including IL-1β, TNF-α, and IFN-γ. In turn, these 
cytokines stimulate the nearby astrocyte–neuron to 
produce further amounts of Aβ42 oligomers, thus 
activating more Aβ42 production and dispersal 23. 
Oligodendroglia (OLGs) is also associated with 
neurons–astrocyte complex; Aβ oligomers also results in 
its destruction
27
. Aβ oligomers aggregates are 
considered to be responsible for the neuronal and 
vascular degeneration in AD brains 
28
. It results in 
oxidative stress, a situation to which OLGs are 
particularly susceptible because their reduced 
glutathione (GSH) content is low and they have a high 
concentration of iron, thus presenting an impaired 
ability to scavenge oxygen radicals 
28
. It has also been 
reported that Aβ42 oligomers possesses an increased 
capability for damaging cholesterol rich membranes, 
such as those found in OLGs and myelin 
28,30
. 
Previous studies about the receptors pharmacology of 
Aβ have shown that Aβ42 monomers activate the 
neuroprotective signaling of insulin-like growth factor-1 
receptor (IGF-1R), while Aβ42 oligomers target a host 
of neurons’ and astrocytes’ membrane receptors, such as 
the scavenger receptor for advanced glycation end 
products (RAGE), Frizzled receptor, insulin receptor, 
NMDA-glutamate receptor, p75 neurotrophin receptor 
(p75NTR), α7 nicotinic ACh receptor (α7nAChR), 
ApoE receptors, formyl peptide receptor-like 1 
(FPRL1/2), cellular prion protein (PrPc) acting as an  
Aβ oligomer receptor, and the calcium-sensing receptor 
(CaSR) 
31,32. Removal of Aβ oligomers from the brain 
occurs by several pathways including proteolytic 
degradation by the proteases neprilysin and insulin 
degrading enzyme (IDE), uptake by astrocytes and 
microglia, passive flow into the cerebrospinal fluid and 
sequestration into the vascular compartment by soluble 
form of the low-density lipoprotein receptor related 
protein 1 (LRP1) 
33,34
. The effect of NO on IDE-
mediated degradation of Aβ has been studied and it has 
been shown that increased NO levels,which have been 
observed in AD, can decrease IDE enzymatic function, 
potentially resulting in increase in Ab oligomers 
deposition in the brain and development of AD 
35
. 
Recently it has been shown that there is a ‘‘contagion’’ 
like diffusion of Aβ42 oligomers and 
hyperphosphorylated tau oligomers via exocytosis 
(synapses) or exosomes to closely associated target cells 
(astrocytes and oligodendrocytes), which in turn become 
producer cells of Aβ and tau oligomers 36. Experimental 
evidence have shown that intracerebral (i.c.) 
administration of minute amounts of brain extract 
containing misfolded Aβ from patients with AD or from 
Aβ-APP transgenic (tg) mice induces cerebral b-
amyloidosis and related pathologies in APP tg mice in a 
time and concentration-dependent manner 
37
. 
The important consequence of the astrocyte–neuron 
interconnections is the astrocytes abilities to promote or 
reduce neurotransmitters release into the synapses they 
envelop with the Ca
2+ 
they respectively let out or take up 
during their Ca
2+
 waves 
27. When neurons Aβ42 
production exceeds the safe limit, toxic Aβ42 oligomers 
start spilling out of the neurons and onto their 
enveloping astrocytes both cell types being empowered 
with Aβ42 oligomer-binding receptors besides 
accumulating or dispersing in the extracellular 
surrounding 
23
. Because of the intimate physical and 
functional interdigitations in the neurons client group, 
the Aβ42 oligomers releases by the neuron can directly 
bind to the α-7nAChRs of its partner astrocytes. The 
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signals from these receptors induce the astrocytes to 
exocytose the glutamate they have been taking up from 
the neuronal synapses 
38
. The discharged glutamate 
activates the extrasynaptic NMDARs of the astrocytes’ 
partner neurons 
37,35
. The resulting signals trigger Ca
2+
 
surges evoking a cascade of events, including 
dysfunctional mitochondria pumping out ROS, which 
inflict an oxidative damage, caspase 3 activation, tau 
hyperphosphorylation, excess production of NO, ROS 
and VEG-F thereby destroying dendritic spines and 
neuronal synapses and severing communications within 
the astrocyte’s neurons and beyond 32. Armato and 
others have shown that CaSRs (present on the cell 
membranes of astrocytes and neurons on which Aβ42 
oligomers binds) selective allosteric antagonist 
(calcilytic) NPS 2143 specifically stops the excess 
release of endogenous Aβ42 from the Aβ25–35-exposed 
human astrocytes and neurons 
32,38
. 
 
 
Figure 1: Diagrammatic presentation of APP processing pathways
39
. 
 
INTRANASAL DELIVERY 
Intranasal nose to brain (N2B) delivery to the upper 
third of the nasal cavity bypasses the blood-brain barrier 
to rapidly target therapeutics to the CNS along the 
olfactory and trigeminal neural pathways (for excellent 
summary see 
40
). The N2B route of administration 
provides a non- to minimal-invasive method of 
bypassing the BBB. 
Anatomy and histology of the nasal cavity 
The nasal cavity is divided longitudinally by the nasal 
septum and extends from the nostrils to the nasopharynx 
(roughly 12–14 cm), but has an impressively large 
mucosa surface area (about 160 cm2) 
40,41
. The frontal 
and lateral views are shown in Figure 2. Three 
turbinates (also called conchae) are the cause for the 
large surface area and their biological function is to 
humidify, warm and filter the inspired air. Nasal 
secretions and inhaled particles are transported to the 
nasopharynx via mucociliar clearance, where they are 
swallowed or expectorated. Importantly, the nasal 
mucosa provides very important immune function since 
countless inhaled pathogens are filtered here and 
transported to the nasopharynx-associated lymphoid 
tissue 
42
. Therefore, intranasal vaccinations like 
FluMist® replace more and more injection-associated 
vaccinations 
The nasal mucosa consists of four different epithelia: 
respiratory, olfactory, squamous and transitional 
epithelium 
43
. The squamous epithelium covers the nasal 
vestibule from the nostrils to the anterior part of the 
turbinates and harbours hairs and glands. The 
transitional epithelium is located at the transitions 
between the other three types of epithelium and appears 
not to have a relevant role in intranasal delivery. 
The nasal respiratory epithelium is a pseudostratified 
columnar secretory epithelium that is formed by ciliated 
cells, goblet cells, intermediate cells and basal cells. The 
tissue shares high similarity to therespiratory epithelium 
of the lung and covers up to 90 % of the nasal cavity in 
humans and roughly 50 % in rodents 
40
. Through close 
contact with inspired air, it warms and humidifies the air 
and air-borne particles and pathogens are removed. 
Different serous glands produce the nasal mucus and 
nasal secretion that are propelled from the ciliated cells 
to the nasopharynx. The mucus is well characterized and 
creates a mild acidic and antibacterial milieu with a pH 
of 5.5 - 6.5 
41
. The nasal respiratory epithelium is 
innervated by the trigeminal nerve, the fifth of the 
cranial nerves. Numerous intraepithelial trigeminal 
fibres are located near the basal region of the 
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epithelium; some of them extending outward to nearly 
reach the epithelial surface stopping at the line of tight 
junctions about 1 μm from the surface 44. The largely 
branched trigeminal nerve projects mainly but not 
exclusively to the brainstem and is highly implicated 
into N2B transport 
44,45
. The respiratory epithelium has a 
large surface and is highly perfused; hence well suitable 
for the systemic absorption of drugs 
46
. 
 
Figure 2: The anatomy of the human nasal cavity. The 
olfactory region permits the transport of APIs to the CSF and 
the olfactory bulb. (A) frontal view with inferior, middle and 
superior turbinate. (B) lateral view with cribriform plate, 
olfactory bulb and CSF in close vicinity to the olfactory 
region. The nasopharynx-associated lymphatic tissue (NALT) 
has immunological functions and is located in lower part of the 
nasal cavity close to the nasopharynx47. 
The olfactory cleft at the roof of the nasal cavity up to 
the superior parts of the turbinates is covered with 
olfactory epithelium. In humans the olfactory region 
comprises up to 10 % of the surface area of the nasal 
epithelium while accounting for about 30 % of the 
surface area in rodents 
38
. The olfactory epithelium is 
formed by columnar epithelial cells, olfactory neurons, 
supporting cells, basal cells and Bowman’s glands 41. 
Olfactory neurons are the only neurons having their cell 
bodies located in a distal epithelium and their non-
motile cilia processes extend into the mucus hence being 
in direct contact to the environment (Figure 3). 
Turbulences at the olfactory cleft increase the residence 
time of the inspired air to increase the interaction of the 
olfactory receptors with odorants. Hence, small number 
of odorant substances can be detected 
41
. The 
unmyelinated axons of olfactory neurons spread through 
the basal lamina and form the fila olfactoria nerve 
bundles enclosed by olfactory ensheathing cells and 
olfactory nerve fibroblasts 
48
. The ensheathed nerve 
bundles travel through the cribriform plate of the 
ethmoid bone into the CNS and terminate at the 
olfactory bulb that project directly to the piriform 
cortex, amygdala, entorhinal cortex and olfactory nuclei 
49
. Compared to the respiratory epithelium the olfactory 
region is less perfused, but still well vasculated. The 
serous mucus produced by the Bowman'sglands is not 
well characterized in the literature. The lamina propria 
underneath the olfactory epithelium harbours blood and 
lymphatic vessels in addition to immune cells connected 
to the deep cervical lymph. 
 
Figure 3: Postulated N2B transport mechanism: dispersed 
drug particles (coloured in green) are inspired with the aid of a 
nasal pump spray or an aerosol generator. Drug molecules 
depositing at the olfactory region diffuse through extracellular 
pathways (green arrows) to the CSF (see left side) or being 
transported via intracellular pathways to the olfactory bulb 
(see right side) and from here to other parts of the CNS47. 
ABSORPTION AND TRANSPORT MECHANISM 
OF THE N2B ROUTE 
Numerous studies have demonstrated central effects of 
N2B delivered drugs in rodents, most of these studies 
did not show pharmacokinetic (PK) data or evidence for 
brain uptake. Hence, the PK and transport mechanism is 
still far from being elucidated. It appears that intranasal 
delivery is a combination of different pathways 
40
. It was 
found that crossing of the epithelial barrier can include 
intracellular or extracellular pathways. Intracellular 
pathways across the olfactory epithelium include 
endocytosis into olfactory neurons shown for several 
viruses and some proteins like peroxidase or albumin 
50,51
 or transcytosis across supporting cells to the lamina 
propria. In addition, the intracellular uptake by 
endocytosis and transcytosis across the respiratory 
epithelium into trigeminal nerve processes or basal 
lamina, respectively, has been observed 
52,53
. 
Paracellular diffusion through epithelial tight junctions 
to the underlying basal lamina is the dominant 
extracellular transport pathways across either the 
olfactory or respiratory epithelia (Figure 2) 
40
. The 
permeability of the nasal epithelium is comparable to 
the intestinal epithelium 
54
. The use of absorption 
enhancers like the natural polymer chitosan or lipophilic 
additives can increase the paracellular passage 
55
. 
After uptake to or through the epithelium, different 
transport pathways have been implicated. N2B delivery 
of radioactive labelled IGF-1 and interferon in rodents 
and monkeys seemed to occur along trigeminal and 
olfactory nerves and to reach first the brainstem and 
olfactory bulb before the proteins are distributed over 
the CNS 
56,57
. Molecules being taken-up via intracellular 
pathways continue their passage via anterograde axonal 
transport. Peroxidase is likely to be purely transported 
with axonal transport and kinetic studies match very 
well with mathematical predictions taking into account 
the transport rate 
40
. Drugs that have been taken-up by 
transcellular diffusion and convection can be absorbed 
by the lymphatic or vascular system (and thereby having 
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a low probability of entering the brain) or diffuse to 
perineural or perivascular spaces and thereby enter the 
cranial compartment. The perineural spaces of the 
olfactory and trigeminal nerves seem to allow transport 
to the CSF of the subarachnoid space 
58
. However, some 
studies suggest that N2B transported substances may be 
present in the brain without being detectable in the CSF 
54
. Mathematical predictions, however, strongly suggest 
that convection/bulk flow along olfactory and trigeminal 
nerves is the most plausible mechanism 
40
. 
ADVANTAGES OF NASAL ROUTE 
 It provides Easy accessibility and needle free drug 
application. 
 The drug can be administered without the necessity 
of trained personnel facilitates (self-medication). 
 Improving patient compliance compared to 
parenteral routes. 
 It provides good penetration of, especially 
lipophilic, low molecular weight drugs through the 
nasal mucosa. 
 It provides rapid absorption and fast onset of action 
due to a relatively large absorptive surface and high 
vascularization. 
 Nasal administration of suitable drugs would 
therefore be effective in emergency therapy as 
alternative to parenteral administration routes. 
 It avoids the hepatic first-pass metabolism and thus 
potential for dose reduction compared to oral 
delivery. 
  Potential for direct delivery of drugs to the central 
nervous system via the olfactory region under 
bypassing the blood-brain-barrier. 
 Direct delivery of vaccine to lymphatic tissue and 
secretory immune response at distant mucosal sites. 
DISADVANTAGES OF NASAL ROUTE 
 Residence time of drug reduces due to the 
mucociliary clearance. 
 It is not applicable to all drugs. 
 Due to the lack of adequate aqueous solubility it 
shows insufficient absorption. 
 Depending on aqueous solubility of drug it requires 
high volume of dose (25-200ml). 
 Some drugs can cause nasal irritation. 
 Some drugs may undergo metabolic degradation in 
the nasal cavity. 
 It is less suitable for chronically administered drugs. 
 Those drugs which require sustained blood levels 
should not be considered for nasal delivery as there 
is no conventional way of formulating sustained 
release type nasal dosage forms. 
LIMITATIONS OF INTRANASAL DRUG 
DELIVERY 
 The absorption enhancers used to improve nasal drug 
delivery system may have histological toxicity which 
is not yet clearly established. 
 Absorption surface area is less when compared to 
GIT. 
 Once the drug administered cannot be removed. 
REASON FOR DEVELOPMENT OF NASAL 
DELIVERY 
Nasal drug delivery is a useful delivery method for 
drugs that are active in low doses and show minimal or 
no oral bioavailability. The nasal route circumvents 
hepatic first pass elimination associated with the oral 
delivery; it is easily accessible and suitable for self-
medication. Currently, two classes of nasally delivered 
therapeutic agents are on the market. The first one 
comprises low molecular weight and hydrophobic drugs 
for the treatment of the nasal mucosa and sinus, 
including decongestants, topical steroids, antibiotics and 
other (OTC) products. The second class encompasses a 
few drugs, which have sufficient nasal absorption for 
displaying systemic effects. Important candidates are the 
compounds, generally administered by injection and 
hardly absorbed after oral administration, due to their 
instability in the gastrointestinal tract, poor absorption 
properties, and their rapid and extensive biotrans-
formation 
59
. 
INTRANASAL DRUG DELIVERY FOR 
ALZHEIMER’S DISEASE TREATMENT 
Intranasal (i.n.) delivery has come to the forefront as an 
alternative to invasive delivery methods. Nasal 
administration of pharmacologically active molecules, 
first developed by Frey in 1991, enables their potential 
absorption to the CNS bypassing the limitations of the 
blood--brain barrier (BBB) because of the unique 
connections that the olfactory and trigeminal nerves 
provide between the brain and external environment 
60
. 
Possible mechanisms of transport of active molecules 
may involve a combination of axonal transport from the 
olfactory neurons of the olfactory epithelium to the 
olfactory bulb, and of extracellular transport routes 
involving bulk flow and diffusion within perineuronal 
channels and perivascular spaces or lymphatic channels 
directly connected to the cerebrospinal fluid (CSF) 
61,62
. 
Advantages of i.n. administration include targeting of 
therapeutics to the CNS with rapid achievement of drug 
levels in the target tissue, and less systemic exposure 
and fewer side effects with avoidance of first-pass 
metabolism 
63,64
 For a therapeutic to be absorbed and 
become bioavailable in the CNS after intranasal 
administration, the drug molecule has to go through the 
mucus layer and cross the epithelial membrane of the 
nasal cavity, thus bypassing the clearance mechanisms 
imposed by the mucociliary apparatus, the broad range 
of metabolic enzymes present in the nasal tissues, and 
the efflux transporters that reside in the apical area of 
ciliated epithelial cells and in the submucosal vessels of 
the human olfactory region 
65,66
. Thus, physiological 
conditions, physicochemical properties of drugs and 
formulations, and the deposition methodologies of the 
formulations represent key factors when the aim is the 
development of a successful nasal medicine. 
Galantamine 
Due to low solubility (35 mg/ml) and dose volume 
limitations (100 μl), the commercially available 
hydrobromide salt of galantamine is not suitable for i.n. 
dosing 
67,68
. The typical oral dose for galantamine is 8 
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mg and therefore it is necessary to increase its solubility 
at least to 80 mg/ml. This goal was brilliantly reached 
by using a counter ion exchange approach, with which 
the traditional counter ion bromide was replaced with 
lactate by using an anion exchange column consisting of 
Q Sepharose 
69
. Lactate was chosen because it favors a 
strong interaction, through hydrogen bonding, with 
water owing to its hydroxyl and carbonyl groups. 
Compared with galantamine hydrobromide, galantamine 
lactate showed remarkable increased solubility (up to ~ 
400 mg/ml) and comparable stability and in vitro 
cellular toxicity. To maximize the bioavailability after 
i.n. administration, galantamine lactate (35-80 mg/ml) 
was formulated with several excipients such as methyl-
b-cyclodextrin 30 mg/ml, didecanoyl- L-a-
phosphatidylcholine 1.7 mg/ml and edetate disodium 
dihydrate 2.0 mg/ml 
70
. The mixture of these three 
permeation enhancers resulted in a fourfold increase in 
the in vitro galantamine permeation across the epithelial 
barrier, high cell viability and low cytotoxicity. This 
formulation was also tested in a rat pharmacokinetic 
model, to study the pharmacokinetic profile of the oral 
versus i.n. administration. The i.n. galantamine had a 
shortened Tmax relative to the oral formulation (5 min 
versus 240 min, respectively) and nearly fourfold 
increase in Cmax (12,100 ± 8000 ng/ml versus 3200 ± 
200 ng/ml). Finally, the hypothesis of reduced GI-
related side effects for i.n. versus oral dosing was tested 
with a ferret model 
71,72
. Clearly, a significant decrease 
in GI-related side effects was observed when 
galantamine was administered by the i.n. route. In 
particular, during the first 4 h after i.n. administration 
only three emesis and retching events were observed, 
whereas 34 events were recorded within 4 h after oral 
administration. Despite the promising results, so far the 
formulation has not been tested in AD patients. 
Physostigmine 
The physostigmine analogue (3aS)-cis-1,2,3,3a,8,8a-
hexahydro- 1,3a,8-trimethyl-pyrrolo-[2,3b]-indol-5-yl-
3,4-dihydro- 2-isoquinolincarboxylate (NXX-066), 
which acts as an ChEI and showed potential for treating 
AD, is well absorbed from the GI tract, but its oral 
bioavailability is poor to moderate in rats and dogs 
because of presystemic metabolism 
73
. The aims of the 
study conducted by Dahlin and BjÖrk were, thus, to 
investigate the systemic absorption of nasally 
administered NXX-066 in rats and to compare the 
uptake of the drug into the CSF after nasal or 
intravenous administration 
74
. Nasal administration of 
NXX-066 resulted in extremely rapid and complete 
absorption into the systemic circulation followed by a 
rapid decline of the plasma concentrations. The 
intravenous and nasal concentration--time profiles of 
NXX-066 were similar, with the mean values of each 
pharmacokinetic parameter not differing significantly 
between the two administration routes. The data 
collected allowed speculation that, as the oral 
bioavailability is poor to moderate owing to presystemic 
metabolism, nasal delivery could be a good alternative 
to the parenteral route for NXX-066 administration. 
Rivastigmine 
For i.n. administration, rivastigmine was formulated in 
conventional multilamellar liposomes obtained by the 
wellknown lipid layer hydration method and using 
cholesterol and soy lecithin as lipid components 
74
. The 
in vitro release studies showed that there was an initial 
burst release followed by a lag phase. The in vivo 
studies showed that intranasally administered liposomes 
significantly increased the exposure and resulted in a 
higher concentration in rat brain. As a matter of fact, the 
AUC (36.13 ± 1.87 mg min/ml) was fivefold higher than 
orally administered free drug (6.58 ± 0.26 mg min/ml) 
and almost threefold higher than free drug administrated 
intranasally (12.99 ± 0.87 mg min/ml). If approved for 
human use, this sustained release of rivastigmine from 
liposomes may be used to reduce the frequency of 
administration. 
Tacrine 
To assess the efficiency of i.n. administration, a tacrine 
solution in propylene glycol was prepared and drug 
concentrations in mice blood and brain were determined 
75
. The study showed that following intranasal 
administration, tacrine reached the rabbit brain quickly 
(Tmax 60 min) compared with intravenous administration 
(Tmax 120 min), suggesting a direct transport into the 
brain from the nasal cavity. This selective localization of 
tacrine in the brain may be helpful in reducing dose, 
frequency of dosing and dose-dependent side effects. 
Starting from these data and in order to increase brain 
bioavailability, a mucoadhesive microemulsion of 
tacrine was prepared and characterized. The mentioned 
microemulsion formulation contained a mucoadhesive 
substance, which favored adhesion to the mucous 
membranes lining the nasal mucosa and improved drug 
targeting to the CNS 
76.
 The results demonstrated rapid 
and larger extent of transport of tacrine into the mice 
brain and fastest regain of memory loss in scopolamine-
induced amnesic mice after intranasal administration of 
tacrine microemulsion. 
17β-Estradiol 
To overcome the low estradiol water solubility (0.008 
mg/ ml), making feasible the nasal administration of an 
effective dose (i.e., 0.1 mg in a volume of 0.1 ml), four 
water-soluble prodrugs have been proposed. They are 
three phenolic esters, 3-N,N-dimethylamino butyl ester 
hydrochloride, 3-N,N-diethylamino propionyl ester 
hydrochloride and 3-N, N,N-trimethylamino butyl ester 
iodide, and one alcoholic ester, 17-N,N-dimethylamino 
butyl ester hydrochloride. All of these were significantly 
more soluble than 17β-estradiol, but only the alcoholic 
prodrug was found to be chemically stable. Moreover, 
the rat CSF concentration of estradiol following nasal 
administration of this compound was higher than that 
following intravenous administration. These preclinical 
data suggest that the drug can reach the CSF via a direct 
pathway through the nasal cavity and that the nasal 
spray solution is the best formulation for this ester. 
Another preclinical attempt to improve the estradiol 
solubility was encapsulation in chitosan nanoparticles 
(final concentration 2 mg/ml) 
77
. Microdialysis studies 
showed that estradiol levels in rat CSF administered 
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with estradiol by means of the nasal route (Cmax 76.4 ± 
14.0 ng/ml and AUC 12788.4 ± 4093.6 ng min/ml) were 
significantly higher than those obtained after i.v. 
injection, despite the much lower estradiol 
concentrations in rat plasma after nasal route 
administration with respect to those measured after i.v. 
injection. It has been seen that chitosan behaves as a 
bioadhesive material and binds strongly to the 
negatively charged mucin through electrostatic 
interactions, thus increasing significantly the half-time 
of clearance of estradiol. 
 
Table 1: Intranasal drugs delivery for treatment of Alzheimer’s disease 
S.No. Drug Dosage Studies Ref. 
1 Galantamine lactate 35-80 mg/ml Preclinical 66,67 
2 Physostigmine analogue (NXX-006) 6.4 mg/ml Preclinical 71 
3 Rivastigmine - Preclinical 72 
4 Tacrine microemulsion - Preclinical 73 
5 Estradiol 0.1 mg/kg 
2 mg/ml 
Preclinical 75 
 
CONCLUSION 
Traditionally mainly  the marketed nasal products are 
used for the management of local diseases in the upper 
respiratory tract such as nasal allergy (e.g. allergic 
rhinitis), nasal infections and nasal congestion, the nasal 
route of delivery is also increasingly exploited for 
systemic delivery of low molecular weight drugs, 
peptide and proteins and for vaccines 
The terms direct nose to brain delivery (Intranasal 
delivery) of drugs; this is evidently a very exciting area 
of research and development due to the potential of 
treating neurodegenerative diseases (e.g. Alzheimer’s) 
more efficiently. However, it is also evident that in order 
to obtain sufficient therapeutic drug levels in the brain it 
will be necessary to develop novel delivery system that 
will be capable to efficiently enhance the transport the 
drug from the nasal cavity to the brain. So far, in general 
for simple drug solutions not more than 1% of the drug 
will be reaching into the brain. 
In review, the advantages of intranasal delivery are 
significant. It is equally rapid and non-invasive. It cross 
the BBB and target the CNS, reducing systemic 
exposure and thus systemic side effects. Even for drugs 
that can cross the BBB, it can reduce systemic side 
effects by reducing the need for the drug to come into 
the systemic circulation. It does not require any 
alteration of the therapeutic agent being delivered and 
should work for a broad range of drugs. 
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